Participants 42 93 4
secondary hyperparathyroidism in stages 3 and 4 CKD
Participants 220 431 5
secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) stage 5. The capsule form of paricalcitol was developed to provide a convenient dosage form for patients with stages 3 and 4 CKD
Participants 441 554 4
Three randomized, placebo-controlled, phase-3 trials were conducted in patients with stages 3 and 4 CKD with SHPT
Participants 1243 1326 3
Two hundred twenty patients participated (n = 107, paricalcitol; n = 113, placebo).
